Forever Young – our exclusive with Sergey Young

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

As the longevity investor’s new fund turns 8 months old this month, we went five for five with Sergey Young.

Longevity.Technology: We often find people have a lot of different answers to this question: What drove you to invest in longevity?

Sergey Young: Like you say, for me it was also a number of different reasons, which led me to set up Longevity Vision Fund and invest in longevity. It all started with a routine visit to a doctor, where my blood tests – which I neglected for 7 years, thinking I was in perfect health – showed that my cholesterol was very high, which put me at risk of heart disease.

The only treatment offered by my doctor at the time was to take statins (cholesterol-reducing drugs), which I would have to take for the rest of my life. I definitely did not want to “live” on a pill forever, so I kept pushing my doctor for alternatives. Eventually, the doctor suggested I try a Mediterranean-style diet (lots of healthy fats, no sugar, etc.), which worked in bringing my cholesterol down to a normal range without any medication at all. Since then, I developed an interest in diet and a lifestyle-based approach to health and longevity, and started consulting everyone – from my amazing housekeeping lady to Forbes billionaires.

However, it was the meeting with Peter Diamandis last year in Vatican City at a conference on regenerative medicine, which was also attended by the Pope, that really kickstarted my longevity mission. Peter is a very inspiring individual, and his XPRIZE Foundation served as a great example of how you can make a difference on a large scale. This is where my mission to expand healthy lifespans of 1 billion people was born, which inspired the establishment of the $100M Longevity Vision Fund to fund longevity breakthroughs and make them affordable and accessible to as many people around the world as possible.

Longevity.Technology: There so many things that make longevity investment risky. Not only is it subject to all of the translational risks seen in more traditional biotech investing, but we’re also so early on in the game that its hard to tell if any of it will live up to its promise. Let’s say I’m a nervous first-time investor in longevity – you run one of the biggest funds in this space, give me some tips on how you assess risk.

Sergey Young: Longevity is a new and exciting field, which does bring certain risks – but at the same time, the potential is unmatched. We are currently undergoing a massive Longevity Revolution, where how medicine is practiced, drugs are developed, is changing. Tech giants are becoming our new healthcare providers. Medicine is becoming more personalized.

I am often invited to speak at longevity and private wealth conferences, where investors ask me the same question. I start by explaining my personal “3 Horizons” framework to help map the longevity space:

  • Horizon 1: technology currently available that has the potential to expand our lifespans to 100 years, such as DIY diagnostics, wearables, digital healthcare delivery, medical software & apps
  • Horizon 2: emerging technology with the potential to expand our lifespans to 150 years, such as genome therapy & editing, stem cell therapy, nano-robots, AI-based diagnostics & drug discovery, smart hospitals
  • Horizon 3: age reversal, brain-computer integration, avatars, Internet of the Body

We invest across all three Horizons, but new investors may want to focus on the first two: early diagnostics, AI in healthcare, life extension technologies in general, and therapies addressing age-related diseases. As for dealing with investment risks, it is really important to have access to the scientific and medical expertise in this field, because scientific due diligence is a key part of the investment decision-making. At Longevity Vision Fund, we have an enviable team of medical and investment professionals, as well as a Scientific Advisory Board of world-class academics.

Longevity.Technology: You’ve recently set up the Longevity Vision Fund. Its early days, but being as there’s quite a bit of portfolio overlap with Bold Capital Partners (the venture fund you work on with Peter Diamandis). What’s its agenda? How do you hope to differentiate it from others (Juvenescence has a strong focus on regenerative medicine, for instance)?

Sergey Young: Longevity is such a new field for investment that there is room for everybody, which inspires collaboration and exchange of knowledge. As such, we don’t tend to compete or actively differentiate ourselves from others in this field – ultimately, we are all in this together with the same goal of improving health and longevity for humanity. All the work we do in this space is complimentary to each other’s. Having said that, at Longevity Vision Fund we do have a focus specifically on affordable and accessible technology.

As for BOLD Capital, we collaborate with them on deal origination and co-investment. So far, out of all our investments, three of them were done together with BOLD. We also love what Juvenescence does in the field – especially their collaborations with the world’s leading scientific hubs. Apart from Juvenescence, we also have other investments, including Life Biosciences and more – and we all share the same vision of extending healthy human lifespans and making the world a better place.

Longevity.Technology: One of the things you’re emphasizing with the Longevity Vision Fund is a focus upon “scalable” technologies, a focus that is really crucial for making longevity a genuine healthcare revolution — as opposed to one that solely benefits the rich. Which technologies in this space do you consider to be scalable and which not?

Sergey Young: Ultimately, the scalability of technology is what makes it accessible and affordable, which is our mission. All of the technology I mentioned earlier – AI, digital healthcare delivery, etc. is aimed at democratizing longevity in general and making it more accessible to society as a whole – regardless of income.

An example from our own portfolio of companies with scalable technologies with breakthroughs that are crucial for a genuine healthcare revolution (or as I call it – Longevity Revolution) includes Insilico, which uses AI for drug discovery and development. In fact, Insilico has recently demonstrated their capability to design, synthesize and validate a novel drug candidate in just 46 days (compared to the typical 2-3 years required for a standard approach used by the majority of pharma companies). This has an unparalleled potential of cutting drug development costs not only by shortening the drug development timeframe, but also by eliminating many false starts, which can occur at any stage of the development process.

Another example from our portfolio is EXO Imaging, which uses AI for ultrasound imaging, developing portable and inexpensive ultrasound device solutions, which require less training to use. However, scalable technologies are obviously not unique to our portfolio. Technology in general is becoming more democratized.

Longevity.Technology: In your upcoming book you’re set to cover the ethical ‘trade-offs’ of extended lifespans. What do you think could be the biggest benefit and the biggest detriment to us all living to 200?

Sergey Young: My upcoming book “Growing Young” focuses mostly on the first two Horizons of Longevity: the technology and the lifestyle changes required for longevity. Ethical trade-offs of living to 200 is a complex topic, which warrants a separate book altogether!

Having said that, I think the goal is not just to have “extended lifespans” or “to live to 200” (although this is my personal aspiration!) but the improved healthspan, the energy and the wellbeing that we could enjoy into the longer years of our lives. The benefits of having your healthy lifespan extended by a quarter (which is completely realistic already) or by a half (achievable in the very near future) are many: starting a second career, going after your goals, spending more time with your loved ones – the biggest benefits of longevity are all personal.

If we look from the perspective of healthy longevity, many detriments commonly associated with longer lifespans, such as an aging population, overburdening the economy, excessive medical costs become irrelevant. Extended healthy longevity means healthier populations, lower medical costs, a more productive workforce, a later retirement. In fact, as an investor, I consider longevity to be the biggest economic opportunity of the century. And from a personal level, having an extended healthy lifespan, which I can use to continue my work in longevity and to spend with my beautiful family of 4 kids – is the best gift of all.

Ben Turner
Staff Writer Ben Turner is a writer and journalist based in London. He graduated in 2015 with a Master’s degree in Physics. He is particularly interested in the translation of early scientific discoveries into cutting-edge tech.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Apollo closes $180m for age-related disease innovations

Apollo Health Ventures fund will drive breakthrough innovations combating age-related diseases. Apollo Health Ventures has announced the final closing of its second venture fund to...

Aging in place: technologies to live long and independently

Our comprehensive market intelligence report provides a deep dive into the opportunities and challenges facing the aging in place industry – and explains why...

Longevica raises $2.5 million for open research platform

$2.5m in funding to support longevity research platform and study to accelerate the discovery of life extension mechanisms, launching in 2022. Longevica, a life science...

A global perspective on consumer longevity data

WHO head of aging and health to present at ARK event focused on the importance of data in the quest for improved longevity. Tomorrow is...

    Subscribe to our newsletter